<DOC>
	<DOCNO>NCT02389816</DOCNO>
	<brief_summary>The purpose study evaluate efficacy two fixed dos Lu AA21004 ( 10 20 mg/day ) 8 week treatment patient MDD Japan</brief_summary>
	<brief_title>A Phase 3 Study Lu AA21004 Patients With Major Depressive Disorder</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group , phase III study ass efficacy safety 8-week treatment two fixed dos Lu AA21004 ( 10 20 mg/day ) Japanese subject major depressive disorder ( MDD ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The participant primary diagnosis recurrent MDD accord DSMIVTR criterion ( classification code 296.3x ) . The participant man woman age 20 75 year ( inclusive ) . The reported duration participant 's current major depressive episode ≥3 month ≤12 month . The participant MADRS total score ≥26 , HAMD17 total score ≥18 Clinical Global ImpressionSeverity Illness ( CGIS ) score ≥4 . The participant follow current past history psychiatric disorder and/or neurological disorder : The participant psychiatric disorder MDD define DSMIVTR ( To assess use MiniInternational Neuropsychiatric Interview ( M.I.N.I. ) ) . However , participant anxiety symptom include study long he/she diagnose anxiety define DSMIVTR . The participant manic , mixed hypomanic episode , MDD psychotic feature , schizophrenia psychotic disorder ( include substancerelated mental disorder , mental disorder due general medical condition ) define DSMIVTR . The participant substanceinduced mood disorder ( except nicotine caffeinerelated disorder ) define DSMIVTR . The participant positive urine drug screen test result . The participant current history clinically significant neurological disorder ( include epilepsy ) . The participant neurodegenerative disorder ( eg . Alzheimer 's disease , Parkinson 's disease , multiple sclerosis Huntington 's disease ) . The participant DSMIVTR axis II disorder . The participant respond 2 adequate antidepressant ( treatment least 6 week duration sufficient dos ) . The participant receive therapy ( e.g . lithium , T3/T4 , Lamotrigine , sodium valproate , carbamazepine , additional atypical antipsychotic , concomitant use antidepressant , etc . ) enhance drug effect current major depressive episode . The participant show significant number major depressive episode past suspected disease MDD . The participant start experience major depressive episode young age suspect disease MDD . The participant significant risk suicide score ≥5 Item 10 ( suicidal thought ) MADRS , attempt suicide within 6 month prior start Screening period . The participant experienced/will experience study environmental change ( e.g . temporary retirement , returnment , change residence , etc . ) determine investigator potential impact efficacy evaluation . The participant clinically significant unstable illness , example , hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , infectious , neoplastic , skin subcutaneous tissue disorder , eye disorder metabolic disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>